According to Citigroup analyst David Lebovitz, Madrigal Pharmaceuticals (NASDAQ: MDGL) continues to be a strong buy as of March 15, 2024. He has increased the price target for the stock from $382 to $389, showing confidence in its potential for growth.
Lebovitz’s positive outlook on Madrigal Pharmaceuticals suggests that he sees promising prospects for the company’s future performance. Investors may want to take note of this updated price target as they consider their investment decisions.
MDGL Stock Surges 12.08% on March 15, 2024: Strong Price Momentum Indicated
On March 15, 2024, Madrigal Pharmaceuticals Inc. (MDGL) experienced a significant surge in its stock performance. According to data from CNN Money, MDGL is currently trading near the top of its 52-week range and above its 200-day simple moving average. This indicates strong price momentum for the company’s stock.
The price of MDGL shares saw a substantial increase on March 15th, with a rise of $29.43 since the market last closed. This represents a notable 12.08% increase in the stock price. MDGL opened at $293.90, which was $50.33 higher than its previous close. This opening price jump signals a strong start for the stock on that particular trading day.
MDGL Stock Performance Analysis: Mixed Results on March 15, 2024
On March 15, 2024, MDGL stock experienced mixed performances based on the financial data available. According to CNN Money, MDGL reported a net income of -$373.63 million for the past year, which represents a 26.5% decrease from the previous year. In the last quarter, the net income improved slightly to -$112.19 million, showing a 0.0% increase from the previous quarter. Earnings per share (EPS) is another important metric to consider when evaluating a company’s financial performance. MDGL reported an EPS of -$19.99 for the past year, which reflects a 16.01% decrease from the previous year. In the last quarter, the EPS improved slightly to -$5.68, showing a 0.0% increase from the previous quarter. Overall, MDGL stock performances on March 15, 2024, were mixed, with some slight improvements in net income and earnings per share compared to the previous quarter. Investors should continue to monitor the company’s financial performance and look for signs of sustained growth and profitability in the future.
